Diabetes device maker Beta Bionics files for $100M IPO
Beta Bionics (BBNX), a maker of insulin delivery devices, has filed for a $100M initial public offering.  Read more here.
The EMBO Journal3d
Developmental beta-cell death orchestrates the islet’s inflammatory milieu by regulating immune system crosstalk
During islet development, beta-cell death, rather than proliferation alone, regulates beta-cell mass and shapes the immune ...